Novartis Ag (NVSEF) Income from Non-Controlling Interests (2009 - 2025)

Novartis Ag (NVSEF) posted Income from Non-Controlling Interests of -$5.0 million for Q4 2025, down 350.0% sequentially from $2.0 million in Q3 2025, and down 350.0% YoY from $2.0 million in Q4 2024.

Novartis Ag (NVSEF) Income from Non-Controlling Interests (2009 - 2025) Analysis & Trends

Novartis Ag (NVSEF) has 15 years of Income from Non-Controlling Interests data on file, last reported at -$5.0 million in Q4 2025.

  • Quarterly Income from Non-Controlling Interests fell 350.0% year-over-year to -$5.0 million in Q4 2025, while the trailing twelve-month figure through Mar 2026 was -$20.0 million (down 2100.0% YoY) and the FY2025 annual result came in at -$17.0 million, down 750.0% from the prior year.
  • Income from Non-Controlling Interests retreated to -$5.0 million in Q4 2025 per NVSEF's latest filing, from $2.0 million in the prior quarter.
  • The five-year high for Income from Non-Controlling Interests was $3.0 million in Q1 2025, with the low at -$17.0 million in Q2 2025.
  • Average Income from Non-Controlling Interests over 5 years is -$1.3 million, with a median of $1.0 million recorded in 2022.
  • Year-over-year, Income from Non-Controlling Interests soared 200.0% in 2022 and plunged 350.0% in 2025.
  • Novartis Ag's Income from Non-Controlling Interests stood at -$2.0 million in 2021, then changed by 0.0% to -$2.0 million in 2022, then soared by 200.0% to $2.0 million in 2023, then changed by 0.0% to $2.0 million in 2024, then sank by 350.0% to -$5.0 million in 2025.
  • Business Quant data shows NVSEF's Income from Non-Controlling Interests at -$5.0 million in Q4 2025, $2.0 million in Q3 2025, and -$17.0 million in Q2 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Inc. Minority (Qtr)
1 Eli Lilly 1,066.16 Bn 1,060.88 Bn 16.22 Bn -
2 Johnson & Johnson 611.69 Bn 589.64 Bn 15.96 Bn -
3 AbbVie 444.34 Bn 434.99 Bn 10.78 Bn 2.00 Mn
4 Astrazeneca 284.94 Bn 277.05 Bn 12.61 Bn 1.00 Mn
5 Merck 224.23 Bn 218.58 Bn 12.09 Bn -3.00 Mn
6 Amgen 195.12 Bn 183.08 Bn 5.87 Bn -
7 Gilead Sciences 156.45 Bn 148.73 Bn 5.52 Bn -
8 Pfizer 136.01 Bn 123.24 Bn -1.21 Bn 8.00 Mn
9 Novartis Ag 113.45 Bn 113.67 Bn - -
10 Novartis Ag - - - -

Historic Data

Download Data
DateValue
Dec 31, 2025 -5.00 Mn
Sep 30, 2025 2.00 Mn
Jun 30, 2025 -17.00 Mn
Mar 31, 2025 3.00 Mn
Dec 31, 2024 2.00 Mn
Sep 30, 2024 -4.00 Mn
Sep 30, 2023 2.00 Mn
Jun 30, 2023 1.00 Mn
Mar 31, 2023 1.00 Mn
Dec 31, 2022 -2.00 Mn
Sep 30, 2022 2.00 Mn
Jun 30, 2022 1.00 Mn
Mar 31, 2022 -3.00 Mn
Dec 31, 2021 -2.00 Mn
Jun 30, 2021 -1.00 Mn
Dec 31, 2020 5.00 Mn
Sep 30, 2020 -3.00 Mn
Mar 31, 2020 -3.00 Mn
Dec 31, 2019 4.00 Mn
Sep 30, 2019 -1.00 Mn